A Phase III, Open-label, 52week Study Evaluating the Safety and Efficacy of KRP-AB1102F DPI in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Phase III, Open-label, 52week Study Evaluating the Safety and Efficacy of KRP-AB1102F DPI in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Aclidinium bromide/formoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Kyorin Pharmaceutical
  • Most Recent Events

    • 07 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top